Clinical Trial Update: Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for intratumoral G100 with or without pembrolizumab or rituximab in follicular non-Hodgkin's lymphoma; trial terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Low Grade Non-hodgkin Lymphoma
• Follicular Non-hodgkin Lymphoma

Drugs mentioned

• G100 (G100)
• Pembrolizumab (pembrolizumab)
• Rituximab (rituximab)

Snippet

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Follicular Low Grade Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-09